Board of Directors
Ann Childress, M.D. | President
Psychiatrist Center for Psychiatry and Behavioral Medicine, Inc.
1st Term: 2018 - 2021
President Elect: 2020 - 2022
President: 2022 - 2024
Gregory Mattingly, M.D. | President Elect
Washington University School of Medicine
1st Term: 2014 - 2018
2nd Term: 2019 - 2022
President Elect: 2022 - 2024
David Goodman, M.D. | Treasurer
Johns Hopkins School of Medicine
1st Term: 2016 - 2019
2nd Term: 2019 - 2022
Secretary: 2020 - 2022
Treasurer: 2022 - 2024
Maria Acosta, M.D.*
1st Term: 2020 - 2023
*Dr. Acosta is serving in a personal capacity
Thomas Brown, Ph.D.
Keck School of Medicine of University of Southern California
1st Term: 2017 - 2020
2nd Term: 2020 - 2023
Martin Katzman, M.D., B.Sc., FRCP(C)
START Clinic for Mood and Anxiety Disorders
Keith McBurnett, Ph.D.
University of California, San Francisco
1st Term: 2017 - 2020
2nd Term: 2020 - 2023
Joel Nigg, Ph.D.
Center for ADHD Research at Oregon Health & Science University
Douglas Russell, M.D.
University of Washington / Seattle Children's
1st Term: 2021 - 2024
Mark Stein, Ph.D.
University of Washington
Secretary: 2008 - 2010
President Elect: 2014 - 2016
President: 2016 - 2018
Past President: 2018 - 2020
1st Term: 2020 - 2023
Dr. Waxmonsky is the Division Chief of Child Adolescent Psychiatry at the Hershey Medical Center, the University Chair in Child Psychiatry at Penn State and Professor of Psychiatry at the Penn State College of Medicine. He completed medical school and general psychiatry residency training at SUNY Buffalo and child fellowship at MGH. Over the past 20 years, he has worked in academics, with a clinical, research and teaching focus on ADHD. His research centers on the integration of medication and behavioral interventions targeting both children and their parents to improve the efficacy and tolerability of ADHD treatments. He has published over 90 peer reviewed articles or book chapters and served as a PI or CoI on over 40 different research trials with funding from NIH, industry and private foundations. He was recently awarded the AACAP Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder for his study examining the growth effects of CNS stimulants. He runs a clinical practice that provides assessment, psychosocial and pharmacological treatment services for ADHD across the lifespan. He also serves as a regional medical director for Pennsylvania’s Child Psychiatry Access Program where he has studied efforts to improve engagement with ADHD treatments in the primary care setting.
As a member of APSARD and a conference attendee, I have always been impressed the breadth of international expertise from academia, industry and the community who come together through APSARD to expand the evidence base for the assessment and treatment of ADHD across the lifespan.
Dr. Keri Rosch is a clinical psychologist conducting research in the Center for Neurodevelopmental and Imaging Research and providing psychological assessments in the Executive Function Clinic the Department of Neuropsychology at the Kennedy Krieger Institute. She also holds an appointment as an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. Dr. Rosch’s broad research interests include examining the interaction of cognition and motivation essential to behavioral control in typical development and implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and related disorders. Dr. Rosch also incorporates physiological and neuroimaging methods to study the interaction of cognitive and motivational processes at a neurobiological level. This work is intended to inform our understanding of the heterogeneity in ADHD as it relates to developmental trajectories and informing personalized medicine.
He has received many honors for his work, including named Fellow of the American Psychological Association (Division 12, 54); Diplomate in Clinical psychology (ABPP), and in 2017 received the lifetime achievement award from Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD).
Dr. Stein has over 100 publications, including articles in Journal of the American Academy of Child and Adolescent Psychiatry, Journal of Child Psychiatry and Psychology, Pediatrics, Nature Medicine, and the New England Journal of Medicine. In 1999, he coedited the textbook, Attention Deficit and Hyperactivity in Children and Adults. Dr. Stein is an Associate Editor for Journal of Attention Disorders and Journal of Child and Adolescent Psychopharmacology.
Dr. Stein has received research support from the National Institute of Health, private foundations, and industry. He has done significant work on medical mimics of ADHD, such a sleep problems and thyroid disease, adaptive dysfunction, dose response and comparative efficacy of ADHD medications, and molecular genetics. Along with collaborators, Drs. Jeffrey Newborn, Andrea Chronis-Tuscano, Margaret Weiss, and Tanya Froehlich, current work is on treating ADHD in parents, pharmacogenomics, and sequencing and personalizing ADHD treatments throughout the lifespan.
Dr. Stein has been a board member of APSARD since it’s founding, past president (2016-2018), and currently chair of the APSARD advisory council.
I am a psychiatrist who has spent much of his career working with those affected by attention deficit hyperactivity disorder. I trained in the United Kingdom and had the opportunity to work in one of the first clinical assessments centers for adult ADHD. An awareness of the gaps in our clinical knowledge led me to pursue research and I moved to the United States to work at the NIMH. Here, I participated in studies examining the neural differences that are associated with ADHD. My recent research focus has been on the genomic, neural and cognitive features that are associated with persistence of ADHD symptoms from childhood into adulthood. I am particularly interested in working with clinical colleagues to build a research agenda that better meets the needs of those with ADHD.
I grew up with a typical ADHD story. I did very well in school but never learned to study. Luckily, I was a nice kid, well liked, never got into trouble; so I got by. High school was harder because I didn’t know how to do the work. I very nearly flunked out of college. Since all I had ever wanted to be was a doctor, and that was unlikely; I got my Mrs. and took a clerical job.
Three years later (1973), an article in Ms. Magazine called The New Nursing, got my career started. Suddenly, there was a career for me, nursing, and it was in the real world of public health. I felt very lucky. I was doing well in school again and loved it.
When my kids got old enough, and with a gentle push from my mother, I went for my Masters in Pediatric Nursing and, in 1993, started my first job as a Nurse Practitioner in Pediatric Neurology. It was there that I first heard of ADHD. Even in Pediatrics, it was never mentioned in school. What an eye-opener it was, having my lifelong difficulties finally explained.
My love for working with ADHD patients and their parents, made me a specialist in 1995. Then, with a gentle push from my collaborating physician, I started a private practice in 1997.
In 2003, I went back to school to earn my degree in Psychiatric Nursing; and this time I didn’t need a push. I was driven to learn about the treatment of more complicated ADHD patients and to expand my practice to include adults. It was an exciting time in my career. Despite this, it was overall disappointing. Given the prevalence of ADHD and the frequency of comorbidity; it shocked me when I saw how many psychiatric providers don’t even look for underlying ADHD before treating symptoms of anxiety or depression. It still baffles me that so many psychiatric practitioners haven’t figured out that life with ADHD is hard, which frequently leads to sadness and worry. In these circumstances, ADHD should always be ruled out, as I have impressed on my NP students over the past 10 years.
I have grown in clinical expertise by regular attendance at programs like MGH’s ADHD Across the Lifespan, and by participating in the CHADD annual conference and APSARD meetings. I have particularly enjoyed giving my presentation on medication delivery systems. In fact, it was at a CHADD conference about 10 years ago that Russell Barkley introduced me to APSARD. I was grateful to finally find a professional group that spoke my language.
Erin Schoenfelder Gonzalez, Ph.D., is an Associate Professor in the Department of Psychiatry and Behavioral Sciences and Adjunct Associate Professor in the Department of Pediatrics at the University of Washington School of Medicine. She is a practicing clinical psychologist at Seattle Children’s Hospital in the Program to Enhance Attention Regulation and Learning (PEARL Clinic). Her specialization and research interests include parent-directed behavioral treatments for ADHD and the association of ADHD with health risk behaviors, especially physical activity and screen use.
As a member since 2015, I have benefited greatly from connecting and sharing knowledge through the APSARD community and appreciate the opportunity to contribute to the future of the organization. In particular, I am excited to promote early career opportunities for new members, highlight issues of equity and access in the ADHD treatment, and continue to grow APSARD’s focus on child and family health promotion.
My name is Margaret (Maggie) Sibley, Ph.D. and I am an Associate Professor of Psychiatry & Behavioral Sciences at the University of Washington School of Medicine and a researcher and psychologist Seattle Children’s Hospital. My research focuses on longitudinal trajectories of ADHD and their implication for clinical diagnosis in individuals age 12 and older. I also conduct National Institute of Mental Health and Institute of Education Sciences-funded work on adapting evidence-based interventions for ADHD to under-resourced school and community contexts. I serve on the professional advisory board of CHADD, the editorial advisory board of Attention magazine, and the program planning committee of APSARD. I am a junior member of the MTA Cooperative Group and the author of a book on treating ADHD in adolescents (2016, Guilford Press). I am passionate about team science and cross-cultural collaboration, innovative methods to promote design quality in research, and offering research mentorship to junior colleagues.
*Dr. Acosta is serving in a personal capacity.
I am Professor of Psychiatry and Behavioral Sciences and of the MIND Institute at the University of California, Davis. I direct the Attention, Impulsivity, Regulation (AIR)/ADHD Program at the UC Davis MIND Institute. My work is translational in nature where I use cognitive neuroscience and behavior analytic principles to investigate attention, impulsivity and hyperactivity in children, adolescents, and adults in typical development and in ADHD. I conducted some of the earliest studies of functional neuroimaging in adults with ADHD, particularly in working memory, starting in the early 1990s. I currently apply fMRI, diffusion tension imaging (DTI), eye-tracking, behavioral and clinical measures in my research. For several years, I have been testing and developing tech-based interventions, including game play and virtual reality technology geared toward improving attention and self-control in individuals with ADHD and disorders with elevated rates of ADHD symptoms (e.g., autism, Fragile X). My goal is to develop targeted, precision health interventions, based on the neuroscience findings of ADHD and other relevant factors (e.g., community, developmental period, etc.). I have been awarded several grants from NIH and other federal agencies for my work in ADHD, autism and substance use disorders.
I am also active in training translational scientists across UC Davis and its NIH-funded Clinical and Translational Science Center (CTSC) where I direct the Mentored Clinical Research Training Program (MCRTP), the Mentoring Academy for Research Excellence (MARE) program and serve as associate director for the NIH-funded TL1 (i.e., T32) pre- and post-doctoral training program and team science endeavors in clinical and translational research. My work in this realm includes involvement in workforce development for translational science in national endeavors through the NIH National Center for Advancing Translational Science (NCATS) network.
I am motivated to serve on the APSARD Board of Directors as this is the leading organization bringing scientists, clinicians and other critical stakeholders together to further the science and care of persons with ADHD with evidence-base practices. APSARD fills an essential gap in advancing the scientific needs, advocacy and training of stakeholders to address the needs of the ADHD population, which has received less attention than is warranted given the high prevalence of ADHD and the myriad of challenges encountered by their families. I will work to continue to raise awareness in the scientific, professional, and lay community about the importance of advancing ADHD science and the education of its stakeholders. I bring to the Board my personal experience in working with diverse disciplines and scientists (e.g., neuroscience, behavior analysis, epidemiology, computer science, biomedical engineering, etc.) and team science principles to advance how we study ADHD. This includes bringing in scientists in areas not typically involved in ADHD to participate in APSARD activities. Finally, I have a lengthy history of developing formal mentoring programs, focused on enhancing relationships between mentors and mentees and pleased to offer my expertise in this area.
Kevin Antshel, PhD, is Professor of Psychology, Director of the Clinical Psychology doctoral program and Director of the ADHD Lifespan, Treatment Education and Research (ALTER) program at Syracuse University. He is also an Adjunct Associate Professor of Psychiatry at SUNY-Upstate Medical University in Syracuse, NY. Dr. Antshel is an active researcher and clinician and has specialized in ADHD for nearly 20 years. He has had the pleasure of training hundreds of doctoral students, residents in psychiatry, pediatrics and family medicine who have rotated through the ALTER clinic.
His research interests focus on understanding the heterogeneity of ADHD, especially ADHD in the context of medical disorders such as 22q11.2 deletion syndrome and phenylketonuria. Clinically, Dr. Antshel has focused on developing and testing innovative psychosocial treatments for adolescents and young adults with ADHD and associated conditions. More recently, Dr. Antshel has focused on issues related to college students with ADHD including how best to reduce stimulant misuse on college campuses.
Dr. Antshel has over 125 peer-reviewed publications, including papers in JAMA Psychiatry, Journal of the American Academy of Child and Adolescent Psychiatry, Journal of Child Psychology and Psychiatry, Psychological Medicine, Journal of Clinical Child & Adolescent Psychology and the American Journal of Psychiatry. He is on the editorial boards of the Journal of Attention Disorders, the ADHD Report and the Journal of Abnormal Child Psychology. In 2014, he co-edited an issue of Child and Adolescent Psychiatric Clinics of North America with Stephen Faraone, Ph.D. Dr. Antshel has served previously on the Scientific Program Committees for APSARD and the World Congress on ADHD. He regularly serves as a grant reviewer on NIH and international review committees.
Dr. Antshel is interested in joining the APSARD Board of Directors to both give back to APSARD as well as participate in strategic planning for the future.
Dr. Behrens is a workflow/efficiency minded and "technologically psychiatrist" (for whatever that may mean) with clinical interest Adult ADHD and the use of technology to improve and expand the patient physician. Throughout his time in residency and as faculty, his clinical interests and specialization drifted to the evaluation and treatment of ADHD in adults where he often worked with high functioning professionals in various time/travel intensive work roles. He soon came to realize the logistical difficulties that such patients face in terms of maintaining treatment and began envisioning ways to utilize technology to more conveniently meet patient/physician needs. While advising and networking with various healthcare startups, he learned the merits of lean-model processing and later,
During his "mid-thirties crisis," made the difficult decision to leave academic medicine to pursue the start-up of a specialized adult adhd practice where he could more readily adapt and evolve with technology and workflows to both meet unique patient needs as well as the personal need to be "ever searching, ever building, ever growing."
Following graduation, he remained as an assistant clinical professor working in an outpatient setting and teaching UW medical students and residents. In 2016, he moved from Madison, WI to Milwaukee, WI to pursue the startup of Envision ADHD serving as CEO and medical director. He is a co-founder of HealthtechMKE in Milwaukee, WI and is a champion of the physician voice in the health technology space. He is currently serving on the American Psychiatric Association (APA) Healthcare Quality Council and on the board of the American Professional Society of ADHD and related disorders (APSARD). He is past chair of the American Medical Association's Young Physician Section Innovation Committee and past president of the Dane County Medical Society.
Mark Bertin, MD is a board certified developmental behavioral pediatrician. He attended UCLA Medical School, completing residency at Oakland Children's Hospital and fellowship in developmental pediatrics at the Albert Einstein College of Medicine. Dr. Bertin is an assistant professor pediatrics at New York Medical College, on faculty for the Windward Teacher Training Institute and the Common Sense Media editorial advisory board, and leads mindfulness classes for parents. Dr. Bertin's book “The Family ADHD Solution” integrates mindfulness into ADHD care, and his blog is available on both Huffington Post and Psychology Today.
Dr. Thomas E. Brown is a clinical psychologist who earned his Ph.D. at Yale University. He is Director of the Brown Clinic for Attention and Related Disorders in Manhattan Beach, California. After 20 years of serving on the clinical faculty of Yale Medical School, he has now joined the clinical faculty of the Dept. of Psychiatry & Behavioral Sciences at the Keck Medical School of the University of Southern California as a clinical associate professor. In May, 2017 he relocated his clinic from CT to Manhattan Beach, CA. Dr. Brown is author of Smart but Stuck: Emotions in Teens and Adults with ADHD (Jossey-Bass/Wiley, 2014), A New Understanding of ADHD in Children & Adults: Executive Function Impairments (Routledge, 2013) and the prize-winning Attention Deficit Disorder: The Unfocused Mind in Children and Adults.(Yale Press, 2005). He edited ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults (American Psychiatric Press, 2009) and is author of the Brown ADD Scales (Pearson). His most recent book is Outside the Box: Rethinking ADD/ADHD in Children and Adults--A Practical Guide (American Psychiatric Publishing, 2017). He has presented symposia and workshops throughout the US and in more than 40 other countries. His website is: www.BrownADHDclinic.com
Dr. Dixon is licensed clinical psychologist and Clinical Professor in the Department of Psychiatry and Behavioral Sciences. She has a long history of work in child psychopathology, specifically the areas of depression, anxiety, PTSD, ADHD and learning differences in children. Currently, Dr. Dixon is the director of clinical management and community outreach for the AIR (Attention, Impulsivity & Regulation) Lab. She is responsible the the clinical and diagnostic fidelity of the AIR Lab research. She also has spent many years educating and training psychology graduate students, interns, and post-doctoral fellows as well as medical students, residents and child psychiatry fellows.
Sam Goldstein, Ph.D. is an Adjust Assistant Professor at the university of Utah School of Medicine and on staff at the University Neuropsychiatric Institute. He is Clinical Director of the Neurology Learning and Behavior Center. The Center conducts evaluation, consultation and provides treatment services to 300 individuals and families each year. Dr. Goldstein has authored fifty trade and science texts as well as over three dozen science based book chapters and thirty peer reviewed research articles. He has also co-authored six psychological tests. He currently serves as Editor in Chief of the Journal of Attention Disorders and sits on the editorial boards of six peer reviewed journals. He is Co-editor of the Encyclopedia of Child Development. Recent books include the Handbook of Intelligence: Evolutionary Theory, Historical Perspective and Current Concepts, Handbook of Resilience - 2nd Edition, Raising Resilient Children with Autism Spectrum Disorders, Handbooks of Neurodevelopmental and Genetic Disorders in Children and Adults, Assessment of Intelligence and Achievement, Assessment of Autism Spectrum Disorders, Handbook of Executive Functioning, Assessment of Impairment and Managing Children's Classroom Behavior: Creating Sustainable Resilient Classrooms. He is the co-author of the Autism Spectrum Rating Scales, Comprehensive Executive Functioning Inventory, Rating Scales of Impairment and the Cognitive Assessment System Second Edition. Currently, he has three books and four psychological tests in development. He has lecture to thousands of professionals and the lay public in the U.S., South America, Asia, Australia, and Europe.
Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University. For the past 20 years, she has been the Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital and for the past 14 years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic. She is Medical Director of the Providers’ Clinical Support System- Medication Assisted Treatments (PCSS-MAT), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director of a SAMHSA-supported State Targeted Response technical assistance grant to states that received funding to address the national opioid epidemic.
She is the principal investigator on several federally funded grants, including a U54 Medications Development grant evaluating novel treatments for opiate and cannabis use disorders, a K24 Mid-Career Investigator Award and collaborates on several other grants. Her current research interests include pharmacologic and psychotherapeutic treatment interventions for cocaine and marijuana use disorder, and treatment approaches for adults with substance use disorders and attention-deficit hyperactivity disorder along with other psychiatric illnesses. Dr. Levin has over 200 articles and book chapters on a wide range of topics including treatments of substance use disorders, assessment and treatment of co-occurring psychiatric illnesses and vulnerabilities associated with substance use disorders. She has served on several advisory panels and ad-hoc federal grant review groups and was as a member of the NIDA – Initial Review Group: Training and Career Development Subcommittee for 8 years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry and past Chair of the APA Council on Addiction Psychiatry.
Dr. Mattingly graduated Summa Cum Laude in chemical engineering before pursuing his medical degree at Washington University where he received a Fullbright Scholarship. He then completed his psychiatry residency at Washington University and is a diplomate of the American Board of Psychiatry and Neurology. He is board certified in psychiatry with a subspecialty in adolescent psychiatry. Dr. Mattingly has received numerous awards and distinctions including the Academy of Child and Adolescent Psychiatry National Leadership Award, the Upjohn Neuropsychiatry Research Award, and the Southern Psychiatric Association
As a principal investigator in over 300 clinical trials, he has been an invited presenter at numerous national and international medical conferences. Having served as a certified examiner for both the NFL and MLB, Dr. Mattingly also sits on the board of directors for Headway House; a “club house” program for individuals with developmental disabilities and chronic mental health conditions in St Louis. Dr. Mattingly’s work has been published in The Journal of Neuropsychiatry and Clinical Neurosciences, The Journal of Clinical Psychiatry, The Journal of Child and Adolescent Psychiatry, Current Psychiatry, CNS
Spectrums and Postgraduate Medicine.
Dr. Mattingly has dedicated the past 25 years of his career to caring for children, adolescents and adults with ADHD and associated conditions. His work on medical education in ADHD received the “Best Poster Award” at this year’s ADHD World Congress in Vancouver. Most importantly, as a parent of a child with developmental disabilities, Dr. Mattingly understands the ongoing need for improved coordination of research, education and clinical care for our patients and their families.